Ticagrelor--is there need for a new player in the antiplatelet-therapy field?

@article{Schoemig2009TicagrelorisTN,
  title={Ticagrelor--is there need for a new player in the antiplatelet-therapy field?},
  author={Albert Schoemig},
  journal={The New England journal of medicine},
  year={2009},
  volume={361 11},
  pages={1108-11}
}
The thienopyridine clopidogrel, which irreversibly blocks the adenosine diphosphate (ADP) receptor P2Y12 on platelets, has become an essential component of therapy in patients with acute coronary syndromes, because it significantly improves the outcomes.1 However, clopidogrel has at least three drawbacks: delayed onset of action, large interindividual variability in platelet response, and irreversibility of its inhibitory effect on platelets (Fig. 1). The two-step activation process, involving… CONTINUE READING
42 Citations
10 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 10 references

Similar Papers

Loading similar papers…